Glycostem® Therapeutics is focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM).
Our mission is to focus on the research, development, production and medical use of NK cells based therapies and work with selected partners looking after patients, staff and the environment.
Our vision is to be the leading innovative NK cell therapy company covering strong unmet medical needs.
Over the last decade we studied the role of NK cells in cancer treatment extensively and pioneered, developed and optimized our in-house NK cell production processes. A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production.
During our phase I safety study we verified our lead product oNKord® (unmodified NK cells) to be a safe therapeutic agent in the field of cellular immunotherapy. Currently we are developing our second product: Chimeric Antigen Receptor (CAR)-engineered NK cells. This second-generation product has dedicated functionality, enhances tumor targeting and prolongs persistence.
The benefits of our products bring to cancer patients:
- Available off-the-shelf – no waiting time to use for highly fragile cancer patients.
- No serious side effects or complications arise from their use.
- Our products are highly pure – potentially contaminated feeder cells are not part of our technology.
- Cost-effective production makes cancer treatment affordable, which allows for successive dosing leading to better outcomes.
Over the last three years we have invested in state-of-the art R&D facilities and a GMP-licensed clean room allowing in-house manufacturing of our lead product oNKord®.